ALLUVI: A DEEP DIVE INTO THE DRUG'S POSSIBILITY

Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist exhibits remarkable efficacy in early trial data, with impressive weight loss observed